We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies. In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Auvelity & Other Drugs Aid AXSM's Growth Amid Stiff Competition?
Read MoreHide Full Article
Axsome Therapeutics’ (AXSM - Free Report) Auvelity (AXS-05) was launched in the United States in 2022 for the treatment of major depressive disorder (MDD), making it the first approved drug in the company’s portfolio.
Auvelity generated sales worth $291.4 million in 2024, reflecting an increase of 124% year over year in the United States. Sales of the drug are being driven by an increase in unit sales volume and the momentum is likely to continue in 2025.
Axsome is also working to expand the label of Auvelity for the larger commercial opportunity in other central nervous system (CNS) disorders like Alzheimer’s disease (AD) agitation and smoking cessation.
Auvelity & Sunosi Aid AXSM
Axsome plans to submit a new drug application (NDA) for AXS-05 in AD agitation to the FDA in the second half of 2025. The company also plans to initiate a phase II/III pivotal study on AXS-05 for smoking cessation later in 2025.
The successful development and potential approval of Auvelity in additional indications will help the drug address a broader patient population and drive sales further.
Axsome acquired U.S. rights to Sunosi, a commercialized drug targeting narcolepsy, from Jazz Pharmaceuticals (JAZZ - Free Report) in 2022. It began selling Sunosi in the U.S. market in May 2022 and in certain international markets in November 2022.
Jazz had received approval for Sunosi as a treatment for narcolepsy in 2019.
JAZZ is entitled to receive a high single-digit royalty from Axsome on net sales of Sunosi in the United States. AXSM out-licensed its ex-U.S. marketing rights of Sunosi to Pharmanovia in February 2023.
Sunosi has become an important revenue driver for Axsome since its acquisition from Jazz. The drug generated sales worth $94.3 million in 2024, reflecting an increase of 26% on a year-over-year basis.
Axsome is evaluating Sunosi in separate phase III studies for treating attention deficit hyperactivity disorder (ADHD), MDD, binge eating disorder and excessive sleepiness associated with shift work disorder.
Top-line data from the FOCUS study and the PARADIGM study, evaluating Sunosi for treating ADHD and MDD, respectively, are expected to be released later in the first quarter of 2025.
New Drugs Approvals an Added Boost for AXSM
In January 2025, the FDA approved Axsome’s Symbravo (meloxicam and rizatriptan) or AXS-07 for the acute treatment of migraine with or without aura in adults. The company expects to launch Symbravo in the United States in about four months. The approval has diversified Axsome’s commercial portfolio and should boost the company’s growth prospects.
This apart, Axsome is nearing two potential approvals for its other pipeline candidates. The company plans to submit an NDA to the FDA seeking approval of AXS-14 for the treatment of fibromyalgia later in the first quarter of 2025.
Axsome also plans to submit an NDA for AXS-12 for treating cataplexy in patients with narcolepsy to the FDA in the second half of 2025.
The steady performance of Auvelity and Sunosi, along with the recent drug approval and encouraging pipeline progress, should maintain momentum for Axsome.
Stiff Competition for AXSM's Products
Though Axsome is riding on the success of Auvelity and Sunosi, competition looms large in the target market as many companies are developing treatments to address various CNS disorders. One such company is Acadia Pharmaceuticals (ACAD - Free Report) , which currently markets its lead drug, Nuplazid (pimavanserin).
ACAD’s Nuplazid is the first and only drug approved by the FDA for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.
Acadia is also developing other pipeline candidates targeting various other CNS disorders. Sunosi is also likely to face competition from Jazz’s sleep disorder drugs, which hold a strong market share.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report predicting the 7 stocks that will soar highest in the coming month.
Image: Shutterstock
Will Auvelity & Other Drugs Aid AXSM's Growth Amid Stiff Competition?
Axsome Therapeutics’ (AXSM - Free Report) Auvelity (AXS-05) was launched in the United States in 2022 for the treatment of major depressive disorder (MDD), making it the first approved drug in the company’s portfolio.
Auvelity generated sales worth $291.4 million in 2024, reflecting an increase of 124% year over year in the United States. Sales of the drug are being driven by an increase in unit sales volume and the momentum is likely to continue in 2025.
Axsome is also working to expand the label of Auvelity for the larger commercial opportunity in other central nervous system (CNS) disorders like Alzheimer’s disease (AD) agitation and smoking cessation.
Auvelity & Sunosi Aid AXSM
Axsome plans to submit a new drug application (NDA) for AXS-05 in AD agitation to the FDA in the second half of 2025. The company also plans to initiate a phase II/III pivotal study on AXS-05 for smoking cessation later in 2025.
The successful development and potential approval of Auvelity in additional indications will help the drug address a broader patient population and drive sales further.
Axsome acquired U.S. rights to Sunosi, a commercialized drug targeting narcolepsy, from Jazz Pharmaceuticals (JAZZ - Free Report) in 2022. It began selling Sunosi in the U.S. market in May 2022 and in certain international markets in November 2022.
Jazz had received approval for Sunosi as a treatment for narcolepsy in 2019.
JAZZ is entitled to receive a high single-digit royalty from Axsome on net sales of Sunosi in the United States. AXSM out-licensed its ex-U.S. marketing rights of Sunosi to Pharmanovia in February 2023.
Sunosi has become an important revenue driver for Axsome since its acquisition from Jazz. The drug generated sales worth $94.3 million in 2024, reflecting an increase of 26% on a year-over-year basis.
Axsome is evaluating Sunosi in separate phase III studies for treating attention deficit hyperactivity disorder (ADHD), MDD, binge eating disorder and excessive sleepiness associated with shift work disorder.
Top-line data from the FOCUS study and the PARADIGM study, evaluating Sunosi for treating ADHD and MDD, respectively, are expected to be released later in the first quarter of 2025.
New Drugs Approvals an Added Boost for AXSM
In January 2025, the FDA approved Axsome’s Symbravo (meloxicam and rizatriptan) or AXS-07 for the acute treatment of migraine with or without aura in adults. The company expects to launch Symbravo in the United States in about four months. The approval has diversified Axsome’s commercial portfolio and should boost the company’s growth prospects.
This apart, Axsome is nearing two potential approvals for its other pipeline candidates. The company plans to submit an NDA to the FDA seeking approval of AXS-14 for the treatment of fibromyalgia later in the first quarter of 2025.
Axsome also plans to submit an NDA for AXS-12 for treating cataplexy in patients with narcolepsy to the FDA in the second half of 2025.
The steady performance of Auvelity and Sunosi, along with the recent drug approval and encouraging pipeline progress, should maintain momentum for Axsome.
Stiff Competition for AXSM's Products
Though Axsome is riding on the success of Auvelity and Sunosi, competition looms large in the target market as many companies are developing treatments to address various CNS disorders. One such company is Acadia Pharmaceuticals (ACAD - Free Report) , which currently markets its lead drug, Nuplazid (pimavanserin).
ACAD’s Nuplazid is the first and only drug approved by the FDA for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.
Acadia is also developing other pipeline candidates targeting various other CNS disorders. Sunosi is also likely to face competition from Jazz’s sleep disorder drugs, which hold a strong market share.